Richard T Hauch

Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies

K. Götze, F. Bassermann, A. Reiter, 2021, Journal of Cancer Research and Clinical Oncology.

Inhibition of PLK1 by capped‐dose volasertib exerts substantial efficacy in MDS and sAML while sparing healthy haematopoiesis

J. Slotta-Huspenina, T. Haferlach, I. Waizenegger, 2019, European journal of haematology.

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

T. Haferlach, K. Götze, F. Bassermann, 2019, Experimental Hematology & Oncology.

Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCTA

S. Rutkowski, W. Woessmann, J. Schrum, 2023, Klinische Pädiatrie.

Elevated RIPK3 correlates with disease burden in myelofibrosis

J. Slotta-Huspenina, F. Bassermann, S. Jilg, 2022, Blood advances.

Impact of COVID-19 Related Restrictions on Infections in Children with Cancer or after Hematopoietic SCT

S. Rutkowski, W. Woessmann, J. Schrum, 2023, Klinische Pädiatrie.

Selective inhibition of BCL-2 is a promising target in patients with high-risk myelodysplastic syndromes and adverse mutational profile

R. Burgkart, J. Slotta-Huspenina, T. Haferlach, 2018, Oncotarget.